Results 1 to 10 of about 9,019 (158)

Telmisartan [PDF]

Hypertension, 2006
In 2002, my colleagues and I1 suggested that blockade of the renin-angiotensin system may prevent diabetes by promoting adipogenesis, thereby allowing redistribution of fat from dangerous visceral and ectopic fat deposits to less-dangerous subcutaneous depots.
europepmc   +5 more sources

Single-Cell Transcriptomics Reveals Immune Modulation by Telmisartan in Colorectal Cancer [PDF]

Cells
Telmisartan, an angiotensin II type 1 receptor blocker with established anti-inflammatory and antihypertensive properties, has been reported to inhibit tumor cell proliferation, yet its impact on the tumor immune microenvironment remains poorly ...
Jinxin Li, Decao Yang, Xiaoyue Wang, Runqing Ju, Shaomeng Chen, Jingyi Zhao, Jiaxing Xu, Jiaxin Chen, Jiayu Ye, Baohui Xu, Qianqian Yin, Yan Wang   +11 more
doaj   +2 more sources

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

EClinicalMedicine, 2021
Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 ...
Ignacio Davolos, Ignacio Fernández Criado, Rodolfo Rothlin   +2 more
exaly   +3 more sources

Targeting AT1 receptors with telmisartan protects SH-SY5Y cells from 6-OHDA induced Parkinsonian neurotoxicity [PDF]

Scientific Reports
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by oxidative stress, neuroinflammation, and α-synuclein accumulation.
Omer Lutfi Gundogdu, Feyza Burul, Elif Tugce Akyol, Ufuk Okkay, Fatma Yesilyurt, Fatih Burak Yildiz, Irmak Ferah Okkay, Mustafa Ozkaraca, Ahmet Hacimuftuoglu   +8 more
doaj   +2 more sources

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats [PDF]

Drug Design, Development and Therapy
Ying Li,1,2,* Wenyu Du,1– 3,* Chunhui Shan,4 Zefang Yu,1 Jing An,1,2 Zhanjun Dong1,2 1Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei Key Laboratory of Clinical Pharmacy ...
Li Y, Du W, Shan C, Yu Z, An J, Dong Z
doaj   +2 more sources

Investigating the effect of telmisartan on acrylamide-induced neurotoxicity through in vitro and in vivo methods [PDF]

Iranian Journal of Basic Medical Sciences, 2023
Objective(s):  Acrylamide (ACR) is an environmental contaminant and neurotoxin. Telmisartan is an AT1 blocker that has neuroprotective properties basically through its anti-oxidant effect.
Zahra Yazadanpanah, Mahboobeh Ghasemzadeh Rahbardar, Bibi Marjan Razavi, Hossein Hosseinzadeh   +3 more
doaj   +1 more source

Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model

Frontiers in Pharmacology, 2023
Objective: Telmisartan is an angiotensin receptor blocker (ARB) that specifically blocks angiotensin II type-1 receptors (AT1R). Telmisartan has been proven to have antidiabetic effects via a variety of mechanisms, and it can be utilized in some diabetic
Ahmed Abd-Eltawab Tammam, Waleed Y. Rizg, Waleed Y. Rizg, Amy Fakhry Boushra, Maha Alhelf, Maha Alhelf, Mohammed Alissa, Ghada F. Soliman, Ghada F. Soliman, Ghada Nady Ouais, Ghada Nady Ouais, Khaled M. Hosny, Hala M. Alkhalidi, Ahmed Magdy Elebiary   +13 more
doaj   +1 more source

Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. [PDF]

PLoS ONE, 2014
Telmisartan, an angiotensin II receptor type 1 blocker, is often used as an antihypertension drug, and it has also been characterized as a peroxisome proliferator-activated receptor-gamma (PPARγ) ligand.
Naoko Koyama, Yoshihiro Nishida, Terukazu Ishii, Toshie Yoshida, Yuichi Furukawa, Hisashi Narahara   +5 more
doaj   +1 more source

Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury

Frontiers in Pharmacology, 2022
Podocytes damage and mesangial cells expansion are two important pathological manifestations of glomerular injury in early diabetes. Telmisartan, as an angiotensin type 1 (AT1) receptor inhibitor, could improve advanced glycation end (AGE) products or ...
Xin Wei, Yabin Ma, Ya Li, Wenzhao Zhang, Yuting Zhong, Yue Yu, Li-Chao Zhang, Zhibin Wang, Ye Tu   +8 more
doaj   +1 more source

Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPARγ

Frontiers in Pharmacology, 2021
Angiotensin II type 1 (AT1) receptor blockers (ARBs), as antihypertensive drugs, have drawn attention for their benefits to individuals with diabetes and prediabetes. However, the direct effects of ARBs on insulin secretion remain unclear. In this study,
Tao Liu, Tao Liu, Tao Liu, Lijuan Cui, Lijuan Cui, Huan Xue, Huan Xue, Xiaohua Yang, Mengmeng Liu, Linping Zhi, Huanhuan Yang, Zhihong Liu, Zhihong Liu, Min Zhang, Qing Guo, Peifeng He, Yunfeng Liu, Yi Zhang, Yi Zhang   +18 more
doaj   +1 more source